Ethnobotanical Anti-Respiratory Syncytial Virus Drugs

描述（由申请人提供）：下呼吸道感染，如 小儿和一些成人的细支气管炎和肺炎是由 呼吸道合胞病毒这些疗法包括有争议的利巴韦林 用于治疗或用于预防的人源化RSV单克隆抗体（Synagis）。 Synagis预防性治疗的每季费用约为5，000美元。在没有 尽管没有有效的疫苗，但RSV仍然是一个严重的健康威胁，必须做出努力， 寻找更有效和更经济的治疗方法。一种创新方法 确定了用民族植物学（EB）制剂治疗RSV感染的方法 在这个项目的第一阶段，这个概念有可能减少 目前的治疗费用。在第一阶段，证明了概念的可行性 通过显着的体外和体内抗RSV活性，其更好或 与利巴韦林相当。这种使用EB制剂的方法， 作为一种治疗目标疾病的方法已经开发得足够详细， 进一步开发活性成分作为抗RSV剂的基础。在 第二阶段，这些EB馏分中的活性化合物将被化学地 净化、鉴定和发展到所需的准备程度， 启动这些化合物作为抗RSV治疗剂临床评价 感染. 拟议商业应用：不可用

DESCRIPTION (provided by applicant): Lower respiratory tract infections such as bronchiolitis and pneumonia in pediatrics and some adults are caused by respiratory syncytial virus. The therapies include the controversial ribavirin for treatment or humanized RSV monoclonal antibodies (Synagis) for prevention. The cost per season for Synagis prophylaxis is about US$ 5,000. In the absence of an effective vaccine, RSV remains a serious health threat and effort must be mounted to find effective and more economical therapies. An innovative approach of treating RSV infection with ethnobotanical (EB) preparations was identified in Phase I of this project and this concept has the potential of reducing the current treatment cost. In Phase I, the feasibility of the concept was proved by the significant in vitro and in vivo anti-RSV activity, which was better or comparable to ribavirin. This approach of using EB preparations with historical use as a treatment to target diseases was developed in enough detail to provide a basis for further development of active ingredients as anti-RSV agents. In Phase II, the active compounds in these EB fractions will be chemically purified, characterized and developed to the level of readiness required to launch clinical evaluation of these compounds as therapeutic agents against RSV infections. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE